Oral drops solution – (10.000 UI + 10.000 UI) / ml

Solution for injection - (0.1%) 1 mg/1 ml

Tablets - 5 mg

Tablets - 500 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Tablets - 850 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Film-coated tablets - 1000 mg

Metformine is an oral antidiabetic which is not chemically or pharmacologically related to sulfonylurea derivatives. Metformine improves glucose tolerance in non-insulin-dependent diabetes mellitus by reducing basal and after-meal blood glucose levels. Metformine also reduces hepatic glucose production, intestinal glucose absorption and improves insulin sensitivity (increases peripheral glucose uptake).

Metformine is indicated in non-insulin-dependent diabetes mellitus when treatment by diet modification alone has not been effective and when the patient is overweight. Metformine may be used alone as initial treatment or in combination with a sulfonylurea derivative.

In insulin-dependent diabetes mellitus, Metformine may be used as adjunctive treatment in patients whose symptoms are difficult to manage.

Tablets - 200 mg

Nicotinamide and nicotinic acid (vitamin PP), are water-soluble vitamin B substances. They are converted in organism to nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). These two products are important coenzymes which are involved in the respiratory chain.

Nicotinic acid deficiency develops when the dietary intake is inadequate. Deficiency leads to the development of a syndrome known as pellagra, characterized by skin lesions, especially on areas exposed to sunlight, with hyperpigmentation and hyperkeratinisation. Other symptoms include diarrhoea, abdominal pain, glossitis, stomatitis, loss of appetite, headache, lethargy, and mental and neurological disturbances.

It is indicated in:

• cases of increased needs for nicotinamide, eg. during pregnancy and breastfeeding;
• debilitated persons and diabetic persons;
• a range of organic and functional diseases of the brain blood vessels (obliterating atherosclerosis, cerebral embolism, spastic migraine);
• organic peripheral vascular disease (Morbus Buerger);
• functional peripheral vascular disease as Raynaud’s disease, acrocyanosis;
• infectious diseases, metabolic disorders, allergies, anorexia, vomiting;
• ophthalmology; used in burns of conjunctiva and cornea from the heat of chemical substances, in diseases of fundus oculi and optic nerve due to vascular diseases;
• otorhinolaryngology; indicated in spastic damage of hearing and vestibular damage;
• stomatitis, glossitis, gingivitis, aphthae;
• dermatology; used in eczema, frostbite, toxic dermatitis, alopecia areata.

Solution for injection - (4%) 40 mg/1 ml

Film – coated tablets – 500.000 IU

Film – coated tablets – 500.000 IU

Solution for injection - (5%) 100 mg/2 ml

Sugar coated tablets - 10 mg

Buskolamin contains as active substance hyoscine butylbromide. Hyoscine butylbromide is a quaternary ammonium salt. This drug, due to its anticholinergic action, possesses antispasmodic properties and it is used to relieve smooth muscle spasms.

Buskolamin 10 mg sugar-coated tablets are indicated in:

• gastrointestinal or genitourinary spasms;
• Irritable Bowel Syndrome.

Gastroresistant capsules - 20 mg

Ulcozol capsules contain the active substance omeprazole. Omeprazole belongs to a group of medicines called proton pump inhibitors. Proton pump inhibitors, like omeprazole, reduce the amount of acid produced in the stomach.

Ulcozol is used for the treatment of the following diseases:

• acid reflux from stomach to oesophag, which causes pain, inflammation and burn (reflux oesophagitis and gastrooesophageal reflux disease)
• ulcers in the upper part of intestine (duodenal ulcers) or in stomach (gastric ulcers)
• if you have ever had NSAID (non-steroidal anti-inflammatory drug) related ulcers, and you should continue taking NSAID, omeprazole may either treat ulcer or prevent it
• ulcers caused by infections from a bacterium called Helicobacter pylori
• excessive acidity in stomach which is caused by a syndrome called Zollinger-Ellison.

Solution for injection - 50 mg / ml

Solution for injection - 100 mg / 2 ml